Wang Jiao, Xie Lijun, Wang Yu, Wang Xiaoqiang, Xi Shuancheng, Zeng Tianfang, Gong Ping, Zhai Xin
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, P. R. China.
Fujian Institute of Microbiology, Changshang District, Fuzhou, P. R. China.
Arch Pharm (Weinheim). 2017 Feb;350(2). doi: 10.1002/ardp.201600307. Epub 2017 Jan 30.
A series of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing (E)-3-hydrosulfonylacrylamido or 1H-imidazole-4-carboxamido moieties were designed, synthesized and evaluated for their cytotoxicity against A549, MKN-45, and HT-29 cancer cell lines in vitro. All the target compounds showed moderate to significant cytotoxic activity against the tested cells with IC values ranging from 0.13 to 2.65 µM. Five of them were further examined for their inhibitory activity against c-Met kinase, which identified compound 30 as a promising agent (c-Met IC = 1.52 nM) with IC values of 0.24, 0.45, and 0.13 µM against HT-29, MKN-45, and A549 cells, respectively.
设计、合成了一系列带有(E)-3-氢磺酰基丙烯酰胺或1H-咪唑-4-甲酰胺基团的新型6,7-二取代-4-苯氧基喹啉衍生物,并对其在体外对A549、MKN-45和HT-29癌细胞系的细胞毒性进行了评估。所有目标化合物对测试细胞均表现出中度至显著的细胞毒性活性,IC值范围为0.13至2.65μM。其中五种化合物进一步检测了它们对c-Met激酶的抑制活性,结果确定化合物30是一种有前景的药物(c-Met IC = 1.52 nM),对HT-29、MKN-45和A549细胞的IC值分别为0.24、0.45和0.13μM。